Optimizing efficacy of amphotericin B through nanomodification

References

• AbraRMHuntCA1981Liposome disposition in vivo. III. Dose and vesicle–size effectsBiocim Biophys Acta666493503
   PubMed Web of Science ®Google Scholar
• Adler-MooreJPChiangSSatoriusA1991Treatment of murine Candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)J Antimicrob Chemother28Suppl B63711778893
   PubMed Web of Science ®Google Scholar
• Adler-MooreJPFujiiGLeeMJA1993In vitro and in vivo interactions of AmBisome with pathogenic fungiJ Liposome Res31516
   Google Scholar
• Adler-MooreJPProffittRT1998AmBisome: long circulating formulation of Amphotericin BWoodleMCStormGLong Circulating Liposomes: Old drugs, New TherapeuticsNew YorkSpringer-Verlag185206
   Google Scholar
• Adler-MooreJProffittRT2002AmBisome: liposomal formulation, structure, mechanism of action and preclinical experienceJ Antimicrob Chemother49Suppl S1213011801577
   PubMed Web of Science ®Google Scholar
• Adler-MooreJP1994AmBisome targeting to fungal infectionsBone marrow transplantation14Suppl 5S3S77703928
   PubMed Web of Science ®Google Scholar
• AlbertMMStahl-CarrollLLutherMF1995Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitisJ Myco Med516
   Web of Science ®Google Scholar
• AlvarJCanavateCGutierrez-SolarB1997Leishmania and human immunodeficiency virus co-infection: the first 10 yearsClin Microbiol Rev102983199105756
   PubMed Web of Science ®Google Scholar
• AmselemSYogevAZawoznikE1994Emulsomes, a novel drug delivery technologyProceedings of the International Symposium on Controlled Release of Bioactive Materials21136869
   Google Scholar
• AnaissieEPaetznickVProffitR1991Comparison of the in vitro antifungal activity of free and liposome-encapsulated Amphotericin BEur J Clin Microb Infect Dis1066568
   PubMed Web of Science ®Google Scholar
• AndesD1999In 39th Interscience Conference on Antimicrobial Agents and ChemotherapySan Franciscoabstract no. 100228
   Google Scholar
• ArikanSRexJH2001Lipid-based antifungal agents: current statusCurr Pharm Des739341511254895
   PubMed Web of Science ®Google Scholar
• BanghamADStandishMMWatkinsJC1965Diffusion of univalent ions across the lamellae of swollen phospholipidsJ Mol Biol13238525859039
   PubMed Web of Science ®Google Scholar
• BanghamAD1992Liposomes: realizing their promiseHosp Pract (Off Ed)275161452605
   PubMed Web of Science ®Google Scholar
• BelayTHospenthalDRRogersAL1991Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine modelJ Med Vet Mycol294194211815035
   PubMedGoogle Scholar
• BermanJDHansonWLChapmanWL1986Antileishmanial activity of liposome–encapsulated amphotericin B in hamsters and monkeysAntimicrob Agents Chemother30847513813512
   PubMed Web of Science ®Google Scholar
• BermanJDKsionskiGChapmanWL1992Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasisAntimicrob Agents Chemother361978801416890
   PubMed Web of Science ®Google Scholar
• BolardJLegrandPHeitzF1991One–sided action of amphotericin B on cholesterol–containing membranes is determined by its self–association in the mediumBiochemistry305707152043613
   PubMed Web of Science ®Google Scholar
• BoswellGWBekerskyIBuellD1998Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in ratsAntimicrob Agents Chemother42263689527770
   PubMed Web of Science ®Google Scholar
• BrajtburgJBolardJ1996Carrier effects on biological activity of amphotericin BClin Microb Rev951231
   PubMed Web of Science ®Google Scholar
• BrajtburgJElbergSKobayashiGS1994Amphotericin B incorporated into egg lecithin–bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycosesAntimicrob Agents Chemother38300068192456
   PubMed Web of Science ®Google Scholar
• BrajtburgJElbergSSchwartzDR1985Involvement of oxidative damage in erythrocyte lysis induced by amphotericin BAntimicrob Agents Chemother27172763985601
   PubMed Web of Science ®Google Scholar
• ClemonsKVHowellKJCalderonL2000Efficacy of intravenous AmBisome against coccidioidal meningitis in rabbitsIn Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and ChemotherapyToronto, CanadaAbstract 2120. Washington, DC. American Society for Microbiology.396
   Google Scholar
• ClemonsKVStevensDA1998Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosisAntimicrob Agents Chemother428999029559804
   PubMed Web of Science ®Google Scholar
• DavidsonRNCroftSLScottA1991Liposomal amphotericin B in drug–resistant visceral leishmaniasisLancet3371061621673494
   PubMed Web of Science ®Google Scholar
• DavidsonRNdi MartinoLGradoniL1996Short–course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)Clin Infect Dis6938438783690
   PubMed Web of Science ®Google Scholar
• de MarieSJanknegtRBakker-WoudenbergIAJ1994Clinical use of liposomal and lipid–complexed amphotericin BJ Antimicrob Chemother33907168089064
   PubMed Web of Science ®Google Scholar
• DromerFBarbetJBolardJ1990Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomesAntimicrob Agents Chemother342055602073097
   PubMed Web of Science ®Google Scholar
• EmmingerWGraningerWEmminger-SchmidmeierW1994Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancerAnn Hematol6827318110875
   PubMed Web of Science ®Google Scholar
• EspuelasMSLegrandPLoiseauPM2002In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheresJ Drug Target105939912683663
   PubMed Web of Science ®Google Scholar
• FrancisPLeeJWHoffmanA1994Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D–mannitol and serum galactomannan as markers of infectionJ Infect Dis169356688106769
   PubMed Web of Science ®Google Scholar
• FromtlingRA1993Amphotericin B cholesterol sulfate complex (colloidal dispersion)Drugs Future1830306
   Google Scholar
• FromtlingRA1995Amphotericin B lipid complexDrugs Future2012934
   Google Scholar
• FujiiG1996Liposomal Amphotericin B (AmBisome): Realization of the drug delivery conceptVesicles12491526
   Google Scholar
• FukuiHKoikeTNakagawaT2003Comparison of LNS–AmB, a novel low-dose formulation of amphotericin B with lipid nano–sphere (LNS), with commercial lipid-based formulationsInt J Pharm2671011214602388
   PubMed Web of Science ®Google Scholar
• FukuiHKoikeTSahekiA1996In 23rd International Symposium on Controlled Release of Bioactive Materials
   Google Scholar
• GangneuxJPSulahianAGarinYJ1996Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisomeAntimicrob Agents Chemother401214188723469
   PubMed Web of Science ®Google Scholar
• GarciaAAdler-MooreJPProffittRT2000Single dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosisAntimicrob Agents Chemother4423273210952575
   PubMed Web of Science ®Google Scholar
• GeorgopapadakouNHWalshTJ1996Antifungal agents: chemotherapeutic targets and immunologic strategiesAntimicrob Agents Chemother40279918834867
   PubMed Web of Science ®Google Scholar
• GokhalePCBarapatreRJAdvaniSH1993Pharmacokinetics and tolerance of liposomal amphotericin B in patientsJ Antimicrob Chemother321331398226404
   PubMed Web of Science ®Google Scholar
• GokhalePCBarapatreRJAdvaniSH1993Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case reportJ Cancer Res Clin Oncol1195695718335676
   PubMed Web of Science ®Google Scholar
• GoldWStoutHAPaganoJF1956Antibiotics Annual 1955–1956WelchHMarti-IbanezFMedical EncyclopediaNew York57986
   Google Scholar
• GraybillJRCravenPCTaylorRL1982Treatment of murine cryptococcosis with liposome–associated amphotericin BJ Infect Dis145748527077097
   PubMed Web of Science ®Google Scholar
• GrollAGiriNGonzalezC1997In 37th Interscience Conference on Antimicrobial Agents and ChemotherapyToronta, Canadaabstract A– 90.
   Google Scholar
• GrollAHGiriNPetraitisV2000Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infections of the central nervous systemJ Infect Dis1822748210882607
   PubMed Web of Science ®Google Scholar
• GuoLSWorkingPK1993Complexes of amphotericin B and cholesteryl sulfateJ Liposome Res3473490
   Google Scholar
• HannINStevensRFPinkertanCR19952nd International Symposium on Febrile NeutropeniaBrussels
   Google Scholar
• HartselSBolardJ1996Amphotericin B: new life for an old drugTrends Pharmcol Sci1744549
   PubMed Web of Science ®Google Scholar
• HayRJ1994Antifungal drugs on the horizonJ Am Acad Dermatol31S82858077515
   PubMed Web of Science ®Google Scholar
• HeinemannVBosseDJehnU1997Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failureJ Antimicrob Chemother40295979302000
   PubMed Web of Science ®Google Scholar
• HerwaldtBL1999LeishmaniasisLancet35411919910513726
   PubMed Web of Science ®Google Scholar
• HiemenzJWWalshTJ1996Lipid formulations of amphotericin B: recent progress and future directionsClin Infect Dis22Suppl 2S133448722841
   PubMed Web of Science ®Google Scholar
• HoeprichPD1992Clinical use of amphotericin B and derivatives: lore, mystique, and factClin Infect Dis14Suppl 1S114S91562682
   PubMed Web of Science ®Google Scholar
• HossainMAMaesakiSKakeyaH1998Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformansAntimicrob Agents Chemother421722259661011
   PubMed Web of Science ®Google Scholar
• HossainMAMaesakiSRazzaqueMS2000Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin BJ Antimicrob Chemother46263810933650
   PubMed Web of Science ®Google Scholar
• JanoffASPerkinsWRSaletanSL1993Amphotericin B lipid complex (ABLC). A molecular rationale for the attenuation of amphotericin B related toxicitiesJ Liposome Res345171
   Google Scholar
• KaryotakisNCAnaissieEJ1994Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic miceAntimicrob Agents Chemother382660627872764
   PubMed Web of Science ®Google Scholar
• KatzNMPiercePFAnzeckRA1990Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patientJ Heart Transplant914172313415
   PubMedGoogle Scholar
• KlepserMEWolfeEJJonesRN1997Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicansAntimicrob Agents Chemother411392959174207
   PubMed Web of Science ®Google Scholar
• KohnoSOtsuboTHaraK1995American Society for Microbiology, Washington D.CPrograms and abstracts of the 35th Interscience Conference on Antimicrobial agents and Chemotherapy131Abstr F109.
   Google Scholar
• KretschmarMAmselemSZawoznikE2001Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes)Mycoses442818611714063
   PubMed Web of Science ®Google Scholar
• LeendersACAPde MarieSten KateMT1996Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosisJ Antimicrob Chemother38215258877535
   PubMed Web of Science ®Google Scholar
• LegrandPRomeroEACohenBE1992Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob.Agents Chemother36251822
   PubMed Web of Science ®Google Scholar
• LegrandPVertut–DoiABolardJ1996Comparative internalization and recycling of different amphotericin B formulations by a macrophage–like cell lineJ Antimicrob Chemother37519339182109
   PubMed Web of Science ®Google Scholar
• Lopez–BeresteinGBodeyGPFrankelLS1987Treatment of hepatosplenic candidiasis with liposomal-amphotericin. BJ Clin Oncol5310173806172
   PubMed Web of Science ®Google Scholar
• Lopez–BeresteinGFainsteinVHopferR1985Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary studyJ Infect Dis151704103973417
   PubMed Web of Science ®Google Scholar
• Lopez-BeresteinGJulianoRL1987Application of liposomes to the delivery of antifungal agentsOstroMJLiposomesNew YorkMarcel Dekker253276
   Google Scholar
• Lopez-BeresteinGMethaRHopferRL1983Treatment and pro-phylaxis of disseminated infection due to Candida albicans in mice with liposome–encapsulated amphotericin BJ Infect Dis147939456842027
   PubMed Web of Science ®Google Scholar
• Lopez-BeresteinG1987Liposomes as carriers of antimicrobial agentsAntimicrob Agents Chemother3167583300535
   PubMed Web of Science ®Google Scholar
• MaesakiS2002Drug delivery system of anti–fungal and parasitic agentsCurr Pharm Des84334012069380
   PubMed Web of Science ®Google Scholar
• MedoffGDismukesWEPappagianisD1992Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Infectious Diseases Society of America and the Food and Drug AdministrationClin Infect Dis15Suppl 1S2742811477243
   PubMed Web of Science ®Google Scholar
• MehtaRTMcQueenTJKeyhaniA1994Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin BChemotherapy40256648082414
   PubMed Web of Science ®Google Scholar
• MehtaRTPoddarSKalidasM1997Role of macrophages in the candidacidal activity of liposomal amphotericin BJ Infect Dis175214178985224
   PubMed Web of Science ®Google Scholar
• MeunierFPrenticeHGRingdenO1991Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trialJ Antimicrob chemother28Suppl B83911778895
   PubMed Web of Science ®Google Scholar
• MeunierFSculierJPCouneA1988Amphotericin B encapsulated in liposomes administered to cancer patientsAnn N Y Acad Sci5445986102850759
   PubMedGoogle Scholar
• MeyerhoffA1999US Food and Drug administration approval of AmBi-some (liposomal amphotericin B) for treatment of visceral leishmaniasisClin Infect Dis28495110391695
   PubMed Web of Science ®Google Scholar
• MillsWChopraRLinchDC1994Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single–centre experience of 133 episodes in 116 patientsBr J Haematol86754607918068
   PubMed Web of Science ®Google Scholar
• MurrayHW1999Kala-azar as an AIDS related opportunistic infectionAids Patient care STDS134596510800524
   PubMed Web of Science ®Google Scholar
• NewRRChanceMLHeathS1981Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomesJ Antimicrob Chemother8371817319979
   PubMed Web of Science ®Google Scholar
• OlsonJHuynhVBunchT2000Differences in efficacy and tissue drug concentrations following treatment of murine pulmonary aspergillosis with AmBisome or AbelcetIn Abstracts of the Fourteenth International Society for Human and Animal Mycoses, Buenos AiresArgentinaAbstract 217, Zurichp.International Society for Human and Animal Mycology228
   Google Scholar
• OstroMJCullisPR1989Use of liposomes as injectable–drug delivery systemsAm J Hosp Pharm461576872672806
   PubMedGoogle Scholar
• OtsuboTMaesakiSHossainMA1999In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatusAntimicrob Agents Chemother43471510049253
   PubMed Web of Science ®Google Scholar
• OtsuboTMaruyamaKMaesakiS1998Long–circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in miceAntimicrob Agents Chemother414049449258
   PubMed Web of Science ®Google Scholar
• PaulMDurandRFessiH1997Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine modelAntimicrob Agents Chemother411731349257750
   PubMed Web of Science ®Google Scholar
• PearsonRDSousaAD1996Clinical spectrum of LeishmaniasisClin Infect Dis221118824958
   PubMed Web of Science ®Google Scholar
• PrenticeHGHannIMHerbrechtR1997A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patientsBrit J Hematol9871118
   PubMed Web of Science ®Google Scholar
• RalphEDBarberKRGrantCWM1993Clinical experience with multilamellar liposomal amphotericin B in patients with proven and suspected fungal infections. ScandJ Infect Dis2348796
   Google Scholar
• RingdenOAndstromERembergerM1994Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporinBone Marrow Transplant14Suppl BS10S147703925
   PubMed Web of Science ®Google Scholar
• RingdenOMeunierFTollemarJ1991Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patientsJ Antimicrob Chemother28Suppl B73821778894
   PubMed Web of Science ®Google Scholar
• SantangeloRPaderuPDelmasG2000Efficacy of oral cochleate–amphotericin B in a mouse model of systemic candidiasisAntimicrob Agents Chemother4423566010952579
   PubMed Web of Science ®Google Scholar
• SchindlerJJWarrenRPAllenSD1993Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune–normal and immune–compromised miceAntimicrob Agents Chemother37271627218109941
   PubMed Web of Science ®Google Scholar
• SchmidtPGAdler-MooreJPForssenEA1998Unilamellar liposomes for anticancer and antifungal therapyLasicDDPapahadjopoulosDMedical Applications of liposomesNew YorkElsevier703731
   Google Scholar
• SculierJPDelcroixCBrassinneC1989Pharmacokinetics of amphotericin B in patients receiving repeated intravenous high doses of amphotericin B entrapped into sonicated liposomesJ Liposome Res115166
   Google Scholar
• SekiJSasakiHDoiMYoshikawaH1994Lipid Nano-Sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration. IVJ Control Release2835253
   Web of Science ®Google Scholar
• SerenoDHolzmullerPLemesreJL2000Efficacy of second line drugs on antimonyl–resistant amastigotes of Leishmania infantumActa Trop74253110643904
   PubMed Web of Science ®Google Scholar
• SperryPJCuaDJWetzelSA1998Antimicrobial activity of AmBisome and nonliposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cellsMed Mycol361351419776826
   PubMed Web of Science ®Google Scholar
• StevensDA1994Overview of amphotericin B colloidal dispersion (amphocil)J Infect28S I45498077690
   PubMedGoogle Scholar
• StormGvan EttenE1997Biopharmaceutical aspects of lipid formulations of amphotericin BEur J Clin Microb and Infect Dis166473
   PubMed Web of Science ®Google Scholar
• SuraritRShepherdMG1987The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicansJ Med Vet Mycol25403132830394
   PubMedGoogle Scholar
• SzokaFCMilhollandDBarzaM1987Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome–intercalated amphotericin BAntimicrob Agent Chemother314219
   PubMed Web of Science ®Google Scholar
• TaylorRLWilliamsDMCravenPC1982Amphotericin B in liposomes: a novel therapy for histoplasmosisAm Rev Resp Dis12561017081822
   PubMed Web of Science ®Google Scholar
• ThakurCPPandeyAKSinhaGP1996Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose–finding studyTrans Royal Soc Trop Med Hyg9031922
   PubMed Web of Science ®Google Scholar
• TollemarJHockerstedtKEriczonB-G1995Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo–controlled studyTransplantation5945507839427
   PubMed Web of Science ®Google Scholar
• TomiiY2002Lipid formulation as a drug carrier for drug deliveryCurr Pharm Des84677412069383
   PubMed Web of Science ®Google Scholar
• TremblayCBarzaMFioreC1984Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in miceAntimicrob Agent Chemother261703
   PubMed Web of Science ®Google Scholar
• van EttenEWOtte–LambillionMvan VianenW1995Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B–desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicansJ Antimicrob Chemother35509197628985
   PubMed Web of Science ®Google Scholar
• van EttenEWSnijdersSVvan VianenW1998Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic miceAntimicrob Agents Chemother422431339736577
   PubMed Web of Science ®Google Scholar
• van EttenEWten KateMTStearneLE1995Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic miceAntimicrob Agents Chemother391954588540697
   PubMed Web of Science ®Google Scholar
• van EttenEWvan den Heuvel-de GrootCBakker-WoudenbergIA1993Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic miceJ Antimicrob Chemother32723398125837
   PubMed Web of Science ®Google Scholar
• van EttenEWvan VianenWHakJ1998Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and fungizone against intracellular Candida albicans in murine peritoneal macrophagesAntimicrob Agents Chemother422437399736579
   PubMed Web of Science ®Google Scholar
• Vertut-DoiAHannaertPBolardJ1988The polyene antibiotic amphotericin B inhibits the Na+/K+ pump of human erythrocytesBiochem Biophys Res Commun1576926972849435
   PubMed Web of Science ®Google Scholar
• WalshTJFinbergRWArndtC1999Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study GroupN Engl J Med3407647110072411
   PubMed Web of Science ®Google Scholar
• WalshTJYeldandiVMcEvoyM1998Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patientsAntimicrob Agents Chemother422391989736569
   PubMed Web of Science ®Google Scholar
• WasanKMMortonRERosenblumMG1994Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high–density lipoproteins: role of lipid transfer proteinJ Pharm Sci831006107965656
   PubMed Web of Science ®Google Scholar
• Wong-BeringerAJacobsRAGuglielmoBJ1998Lipid formulations of amphotericin B: clinical efficacy and toxicitiesClin Infect Dis27603189770163
   PubMed Web of Science ®Google Scholar
• YardleyVCroftSL1997Activity of liposomal amphotericin B against experimental cutaneous leishmaniasisAntimicrob Agents Chemother41752569087483
   PubMed Web of Science ®Google Scholar
• ZarifLGraybillJRPerlinD2000Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse modelAntimicrob Agents Chemother44146369
   Web of Science ®Google Scholar